| Literature DB >> 27460384 |
Lin Yu1,2, Jinguo Liu3, I Weng Lao1,2, Zhiguo Luo4,2, Jian Wang5,6.
Abstract
BACKGROUND: To explore the clinical characteristics and pathological features of epithelioid inflammatory myofibroblastic sarcoma (EIMS) with emphasis on the diagnostic spectrum.Entities:
Keywords: Fluorescence in situ hybridization; Gastrointestinal tract; Inflammatory myofibroblastic tumor; RANBP2-ALK; Soft tissue tumor
Mesh:
Substances:
Year: 2016 PMID: 27460384 PMCID: PMC4962498 DOI: 10.1186/s13000-016-0517-z
Source DB: PubMed Journal: Diagn Pathol ISSN: 1746-1596 Impact factor: 2.644
Fig. 1Endoscopic appearance of EIMS. Colonoscopy examination showed a polypoid mass protruding into the rectum cavity
Fig. 2Imaging features of EIMS. Computed tomography (CT) scan revealed an enormous heterogeneous mass in the pelvic cavity
Fig. 3Histological features of EIMS. a A mesenteric tumor infiltrated the adjacent small bowel wall (40 × original magnification). b The tumor was composed predominantly of sheets of round-to-epithelioid cells with a prominent inflammatory infiltrate (200 × original magnification).c The epithelioid tumor cells showed vesicular nuclei, large and prominent nucleoli, and amphophilic-to-basophilic cytoplasm (400 × original magnification).d A minor spindle cell component was present in all cases (100 × original magnification)
Fig. 4Immunohistochemical and genetic features of EIMS. a Immunohistochemistry for ALK showed a nuclear membrane staining pattern (400 × original magnification). b Case 3 showed ALK cytoplasmic staining with perinuclear accentuation (200 × original magnification). c Diffuse and strong positivity for desmin (200 × original magnification). d Fluorescence in situ hybridization (FISH) showed split apart of the red and green signals, confirming the presence of ALK rearrangement (1000 × original magnification)
Clinical features of 25 cases of epithelioid inflammatory myofibroblastic sarcoma
| Case | Age/Sex | Site | Size (cm) | Multifocal | Treatment | Recurrence | Metastasis | Follow up | Source |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 7y/M | Abdominal cavity | NA | No | SE, CT | Yes (5w, 5 m) | No | NED(5 m) | Ma et al. [ |
| 2 | 7 m/M | Mesentery and omentum | 11 | Yes | SE | Yes (8 m) | No | AWD(8 m) | |
| 3 | 2y/M | Retroperitoneal and abdominal cavity | 10 | No | SE | No | No | NED(36 m) | Patel et al. [ |
| 4 | 34y/M | Liver | 8 | No | SE | Yes (5 m) | No | DOD(5.5 m) | Chen et al. [ |
| 5 | 44y/M | Omentum | NA | Yes | SE, CT, ALKi | Yes (5 m) | Liver (12 m) | AWD(39 m) | Butrynski et al. [ |
| 6 | 41y/M | Omentum | 26 | Yes | ST, CT, ALKi | Yes (12 m) | Liver(12 m) | NED(40 m) | Marino-Enriquez et al. [ |
| 7 | 59y/M | Mesentery of small bowel | 15 | Yes | SE, CT | Yes | No | DOD (12 m) | |
| 8 | 6y/M | Omentum | 10.5 | No | SE, CT | Yes | No | AWD(3 m) | |
| 9 | 28y/M | Mesentery of small bowel | NA | Yes | NA | NA | NA | NA | |
| 10 | 63y/M | Mesentery of small bowel | 25 | No | SE, CT | Yes | No | DOD(3 m) | |
| 11 | 42y/M | Intra-abdominal | NA | No | SE, CT | Yes | No | AWD(13 m) | |
| 12 | 7 m/M | Peritoneum | 10 | No | SE, CT, RT | Yes | No | DOD(36 m) | |
| 13 | 40y/M | Peritoneum | 8 | No | SE, CT, RT | Yes | Lung, liver, and lymph node | ||
| 14 | 31y/M | Mesentery of small bowel | 17.5 | Yes | SE, CT | Yes | No | DOD(11 m) | |
| 15 | 6y/M | Omentum and mesentery | 14 | Yes | SE | NA | NA | NA | |
| 16 | 39y/M | Mesentery of small bowel | 15 | Yes | SE | NA | NA | NA | |
| 17 | 57y/M | Pleura or chest wall | NA | NA | ALKi | NA | NA | NA | Kozu et al. [ |
| 18 | 19y/F | Mesentery of small bowel | 19 | No | SE | Yes(9w) | No | DOD(12w) | Li et al. [ |
| 19 | 39y/M | Mesentery of colon | 15 | No | SE, CT | Yes(4 m) | No | AWD(12 m) | |
| 20 | 22y/M | Mesentery of small bowel | 6 | Yes | SE, CT, ALKi | Yes(3 m, 4 m) | No | AWD(14 m) | Kimbara et al. [ |
| 21 | 37/F | Rectum | 5 | No | SE | No(8 m) | No | NED(8 m) | Current cases |
| 22 | 55/M | Mesentery of ileum | 11 | No | SE, CT | Yes(2 m) | No | NED(10 m) | |
| 23 | 22/M | Mesentery of colon | 20 | Yes | SE, ALKi | Yes(2 m) | No | AWD(14 m) | |
| 24 | 58/F | Omentum | 5.5 | No | SE, CT | Yes(2 m) | No | DOD(8 m) | |
| 25 | 15/F | Transverse colon | 12 | No | SE | No(7 m) | No | NED(7 m) |
ALKi ALK inhibitor, AWD alive with disease, CE cholecystectomy, CT chemotherapy, DOD dead of disease, NA not available, NED no evidence of disease, RT radiation therapy, SE surgical excision
Immunohistochemical and genetic features of 25 cases of epithelioid inflammatory myofibroblastic sarcoma
| Case | Immunohistochemical features | ALK | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| desmin | SMA | H-caldesmon | CD30 | CK | EMA | S-100 | myogenin | IHC | FISH | RT-PCR | |
| 1 | NA | NA | NA | NA | NA | NA | NA | NA | NM+ | + | RANBP2-ALK |
| 2 | NA | NA | NA | NA | NA | NA | NA | NA | NM+ | + | RANBP2-ALK |
| 3 | + | + | - | NA | + | NA | - | NA | PN+ | + | RANBP2-ALK |
| 4 | - | - | NA | - | - | NA | - | NA | NM+ | NA | RANBP2-ALK |
| 5 | + | - | NA | + | - | - | - | - | NM+ | + | RANBP2-ALK |
| 6 | + | - | - | + | - | - | - | - | NM+ | + | RANBP2-ALK |
| 7 | + | + | NA | NA | - | NA | - | - | NM+ | + | NA |
| 8 | + | - | NA | NA | - | NA | - | - | NM+ | + | NA |
| 9 | + | + | NA | + | - | - | - | NA | NM+ | NA | NA |
| 10 | + | - | - | + | - | - | - | - | PN+ | + | NA |
| 11 | + | NA | NA | NA | NA | NA | NA | NA | NM+ | NA | NA |
| 12 | + | NA | - | + | NA | NA | NA | - | PN+ | + | NA |
| 13 | - | + | - | + | - | - | - | - | NM+ | + | NA |
| 14 | + | - | - | + | - | NA | - | - | NM+ | + | NA |
| 15 | + | NA | - | + | NA | NA | NA | NA | NM+ | + | RANBP2-ALK |
| 16 | + | + | - | + | - | NA | - | - | NM+ | + | RANBP2-ALK |
| 17 | + | - | NA | - | + | NA | - | NA | PN+ | + | NA |
| 18 | + | + | - | + | - | - | - | - | NM+ | + | NA |
| 19 | + | + | - | + | - | - | - | - | NM+ | + | RANBP2-ALK |
| 20 | NA | NA | NA | NA | NA | NA | NA | NA | NM+ | NA | RANBP2-ALK |
| 21 | + | - | - | - | - | NA | - | - | NM+ | + | NA |
| 22 | + | - | NA | - | - | - | - | - | NM+ | + | NA |
| 23 | + | - | - | - | - | - | - | - | PN+ | + | NA |
| 24 | + | Focal + | - | - | Focal + | NA | - | - | NM+ | + | NA |
| 25 | - | + | NA | - | - | - | - | - | NM+ | + | NA |
| Total | 86 % (19/22) | 47 % (9/19) | 0 % (0/13) | 61 % (11/18) | 16 % (3/19) | 0 % (0/10) | 0 % (0/19) | 0 % (0/16) | 100 % (25/25) | 100 % (21/21) | 100 % (10/10) |
CK cytokeratin, EMA epithelial membrane antigen, FISH fluroscence in situ hybridization, IHC immunohistochemistry, NA not avaiable, NM nuclear membrane staining, PN cytoplasmic staining with perinuclear accentuation, RT-PCR reverse transcription polymerase chain reaction, SMA smooth muscle actin